NO20100431L - Fremgangsmate for a endre degradering av det humane klokkeproteinet hPeriode1 (hPER1) - Google Patents

Fremgangsmate for a endre degradering av det humane klokkeproteinet hPeriode1 (hPER1)

Info

Publication number
NO20100431L
NO20100431L NO20100431A NO20100431A NO20100431L NO 20100431 L NO20100431 L NO 20100431L NO 20100431 A NO20100431 A NO 20100431A NO 20100431 A NO20100431 A NO 20100431A NO 20100431 L NO20100431 L NO 20100431L
Authority
NO
Norway
Prior art keywords
alter
hperiode1
hper1
ability
directed
Prior art date
Application number
NO20100431A
Other languages
English (en)
Inventor
Cesare Mondadori
Fernando Camacho
George Keesler
Zhengbin Yao
Original Assignee
Aventis Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20100431L publication Critical patent/NO20100431L/no
Application filed by Aventis Holdings Inc filed Critical Aventis Holdings Inc

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Electrophonic Musical Instruments (AREA)

Abstract

Fremgangsmåter for å identifisere testforbindelser som endrer cirkadiske rytmer hos pattedyr og mer spesielt, fremgangsmåter for å bestemme en testforbindelses evne til å endre hCKIS- og -e-fosforylering av et humant periodeprotein. Oppfinnelsen angår også en fremgangsmåte for å bestemme en testforbindelses evne til selektivt å endre fosforylering, interagere med eller alternativt degradere en eller flere humane periodeproteiner i forhold til dens evne til å endre fosforylering, interagere med eller alternativt degradere et forskjellig humant periodeprotein.
NO20100431A 1999-06-08 2010-03-23 Fremgangsmate for a endre degradering av det humane klokkeproteinet hPeriode1 (hPER1) NO20100431L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32774599A 1999-06-08 1999-06-08
PCT/US2000/015633 WO2000075669A1 (en) 1999-06-08 2000-06-07 Screening methods for altering circadian rhythm proteins

Publications (1)

Publication Number Publication Date
NO20100431L true NO20100431L (no) 2002-02-05

Family

ID=23277866

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20015972A NO330241B1 (no) 1999-06-08 2001-12-06 Fremgangsmate for a identifisere forbindelser som endrer fosforylering av det humane klokkeproteinet hPERIODE1 (hPER1)
NO20100430A NO20100430L (no) 1999-06-08 2010-03-23 Anvendelse av en forbindelse for fremstilling av et medikament for a endre den cirkadiske rytme hos et pattedyr
NO20100431A NO20100431L (no) 1999-06-08 2010-03-23 Fremgangsmate for a endre degradering av det humane klokkeproteinet hPeriode1 (hPER1)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NO20015972A NO330241B1 (no) 1999-06-08 2001-12-06 Fremgangsmate for a identifisere forbindelser som endrer fosforylering av det humane klokkeproteinet hPERIODE1 (hPER1)
NO20100430A NO20100430L (no) 1999-06-08 2010-03-23 Anvendelse av en forbindelse for fremstilling av et medikament for a endre den cirkadiske rytme hos et pattedyr

Country Status (15)

Country Link
US (1) US6555328B1 (no)
EP (1) EP1183541B1 (no)
JP (1) JP4583682B2 (no)
KR (1) KR100722176B1 (no)
AT (1) ATE322016T1 (no)
AU (1) AU767800B2 (no)
BR (1) BR0011437A (no)
CA (1) CA2375450C (no)
DE (1) DE60026998T2 (no)
IL (2) IL146729A0 (no)
MX (1) MXPA01011417A (no)
NO (3) NO330241B1 (no)
NZ (1) NZ514603A (no)
WO (1) WO2000075669A1 (no)
ZA (1) ZA200108962B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436628B1 (en) 1998-06-19 2002-08-20 The Rockefeller University Methods of identifying an agent which modulates period and doubletime protein interaction
US6476188B1 (en) 1998-06-19 2002-11-05 The Rockefeller University Clock gene and methods of use thereof
WO2000075669A1 (en) * 1999-06-08 2000-12-14 Aventis Pharmaceuticals Inc. Screening methods for altering circadian rhythm proteins
US7659387B1 (en) * 1999-11-18 2010-02-09 University Of Virginia Transgenic mammals introduced a Period 1 promoter that confers rhythmical expression
GB0103110D0 (en) * 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
AU2002248338A1 (en) * 2001-01-11 2002-07-24 University Of Utah Research Foundation Identification of an advanced sleep phase syndrome gene in humans
WO2004038043A2 (en) * 2002-10-25 2004-05-06 University Of Surrey POLYMORPHISM IN THE Per3 GENE AS A INDICATOR IN THE DIAGNOSIS AND TREATMENT OF CIRCADIAN RHYTHM SLEEP DISORDERS
AU2003293150A1 (en) * 2002-11-27 2004-06-23 University Of Utah Research Foundation Casein kinase i epsilon and casein kinase i delta and sleep in humans
JO2724B1 (en) * 2004-08-19 2013-09-15 افينتس فارماسوتيكالز انك 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors
KR20070045264A (ko) * 2004-08-19 2007-05-02 아벤티스 파마슈티칼스 인크. 카세인 키나제 Ｉε 억제제로서의3-아릴티오인돌-2-카복스아미드 유도체 및 이의 유사체
JO2629B1 (en) * 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
JP2009538597A (ja) * 2006-05-31 2009-11-12 独立行政法人放射線医学総合研究所 光誘導性周期的発現遺伝子及び体内時計システムに影響を与える物質のスクリーニング方法
JP5518479B2 (ja) * 2006-10-25 2014-06-11 ザ ロックフェラー ユニヴァーシティ Ａβ関連障害の処置のための方法およびその組成物
FR2918986B1 (fr) 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
CN105744948B (zh) * 2013-10-14 2020-03-24 南京大学 进食节律提前综合征的识别方法及其应用
KR101600144B1 (ko) * 2013-12-20 2016-03-04 서울대학교산학협력단 일주기 리듬 수면장애 및 시차 부적응에 대한 예방 또는 치료제 스크리닝 방법
WO2015106158A1 (en) 2014-01-09 2015-07-16 Intra-Cellular Therapies, Inc. Organic compounds
US11116754B2 (en) 2015-11-13 2021-09-14 The Trustees Of Columbia University In The City Of New York Inhibition of TOR complex 2 increases immunity against bacterial infection
WO2023129377A1 (en) * 2022-01-03 2023-07-06 The Johns Hopkins University Methods and materials for treating heart attack

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1157137A (ja) * 1997-08-28 1999-03-02 Sanyo Bussan Kk 遊技機用特別図柄表示装置
KR100246893B1 (ko) * 1997-12-29 2000-05-01 윤종용 전자렌지용 도어
WO1999057137A1 (en) * 1998-05-07 1999-11-11 The President & Fellows Of Harvard College Compositions and methods involving regulation of mammalian circadian rhythms
WO2000075669A1 (en) * 1999-06-08 2000-12-14 Aventis Pharmaceuticals Inc. Screening methods for altering circadian rhythm proteins

Also Published As

Publication number Publication date
KR100722176B1 (ko) 2007-05-29
WO2000075669A1 (en) 2000-12-14
NO20100430L (no) 2002-02-05
MXPA01011417A (es) 2002-06-04
IL146729A (en) 2007-06-17
ZA200108962B (en) 2003-01-30
ATE322016T1 (de) 2006-04-15
NO330241B1 (no) 2011-03-14
DE60026998T2 (de) 2007-04-05
DE60026998D1 (de) 2006-05-18
AU5468900A (en) 2000-12-28
IL146729A0 (en) 2002-07-25
NO20015972D0 (no) 2001-12-06
NZ514603A (en) 2003-10-31
JP4583682B2 (ja) 2010-11-17
CA2375450A1 (en) 2000-12-14
JP2003501074A (ja) 2003-01-14
AU767800B2 (en) 2003-11-27
EP1183541B1 (en) 2006-03-29
BR0011437A (pt) 2002-03-05
KR20020033101A (ko) 2002-05-04
US6555328B1 (en) 2003-04-29
NO20015972L (no) 2002-02-05
CA2375450C (en) 2009-04-28
EP1183541A1 (en) 2002-03-06

Similar Documents

Publication Publication Date Title
NO20100431L (no) Fremgangsmate for a endre degradering av det humane klokkeproteinet hPeriode1 (hPER1)
EA199700280A1 (ru) Ингибиторы протеинкиназы с
CY1108655T1 (el) ΘΕΙΟΖΟΛΙΔΙΝ-4-ΟΝΕΣ ΓΙΑ ΤΗΝ ΑΝΑΣΤΟΛΗ ΠΡΩΤΕΪΝΩΝ hYAK3
CY1113312T1 (el) Κυκλικοι αναστολεις κινασης τυροσινης πρωτεϊνων
CY1110679T1 (el) Νουκλεοτιδικες και πρωτεϊνικες ακολουθιες γονιδιων nogo και μεθοδοι βασιζομενες σε αυτες
CY1105836T1 (el) 12, 13-τροποποιημενα παραγωγα εποθιλονης
EA199900758A1 (ru) Малые молекулы, полезные при лечении воспалительных заболеваний
ID26328A (id) Penghambat raf kinase menggunakan urea heterosiklik tersubstitusi aril dan heteroaril
ATE269303T1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
EA200100589A1 (ru) Азабициклоалканы как модуляторы ccr5
EA200200208A1 (ru) Синергитическая композиция
EA200301232A1 (ru) Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы
CY1110530T1 (el) Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων
DK0986382T3 (da) RAF-kinasehæmmere
EA200101133A1 (ru) Способ ингибирования агрегации амилоидных белков и визуализации амилоидных отложений с использованием производных изоиндолина
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
EA200001244A1 (ru) Комбинационная терапия для лечения биполярных расстройств
EA200100958A1 (ru) Производные 4,5-диарил-3(2h)-фуранона как ингибиторы циклооксигеназы-2
EA200100012A1 (ru) Мостиковые инденопирролокарбазолы
CY1105380T1 (el) Προτιμωμενα τμηματα της νευρικης νηματικης πρωτεϊνης και μεθοδοι χρησης αυτων
DE69621799D1 (de) Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
DE3854209T2 (de) Analyse von organischen Substanzen.
ATE73995T1 (de) Verwendung von penicillamin zur behandlung von immunmangelkrankheiten.
EA200500603A1 (ru) ПРОИЗВОДНЫЕ [6,7-ДИГИДРО-5H-ИМИДАЗО[1,2-α]ИМИДАЗОЛ-3-СУЛЬФОНИЛАМИНО]ПРОПИОНАМИДА

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application